KR101631323B1 - 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질 - Google Patents

증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질 Download PDF

Info

Publication number
KR101631323B1
KR101631323B1 KR1020097025293A KR20097025293A KR101631323B1 KR 101631323 B1 KR101631323 B1 KR 101631323B1 KR 1020097025293 A KR1020097025293 A KR 1020097025293A KR 20097025293 A KR20097025293 A KR 20097025293A KR 101631323 B1 KR101631323 B1 KR 101631323B1
Authority
KR
South Korea
Prior art keywords
pas
ifna2b
amino acid
ser
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097025293A
Other languages
English (en)
Korean (ko)
Other versions
KR20100044732A (ko
Inventor
아메 스케라
이나 테오발드
마르틴 스클랍스키
Original Assignee
엑스엘-프로테인 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39776993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101631323(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 엑스엘-프로테인 게엠베하 filed Critical 엑스엘-프로테인 게엠베하
Publication of KR20100044732A publication Critical patent/KR20100044732A/ko
Application granted granted Critical
Publication of KR101631323B1 publication Critical patent/KR101631323B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
KR1020097025293A 2007-06-21 2008-06-20 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질 Active KR101631323B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07012219.7 2007-06-21
EP07012219 2007-06-21
US7170508P 2008-05-14 2008-05-14
US61/071,705 2008-05-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157020384A Division KR101701080B1 (ko) 2007-06-21 2008-06-20 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질

Publications (2)

Publication Number Publication Date
KR20100044732A KR20100044732A (ko) 2010-04-30
KR101631323B1 true KR101631323B1 (ko) 2016-06-17

Family

ID=39776993

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097025293A Active KR101631323B1 (ko) 2007-06-21 2008-06-20 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질
KR1020157020384A Active KR101701080B1 (ko) 2007-06-21 2008-06-20 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157020384A Active KR101701080B1 (ko) 2007-06-21 2008-06-20 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질

Country Status (19)

Country Link
US (2) US8563521B2 (enExample)
EP (2) EP2369005B1 (enExample)
JP (1) JP5351889B2 (enExample)
KR (2) KR101631323B1 (enExample)
CN (1) CN101970678B (enExample)
AT (1) ATE502114T1 (enExample)
AU (1) AU2008266448B2 (enExample)
CA (1) CA2691386C (enExample)
CY (1) CY1111491T1 (enExample)
DE (1) DE602008005596D1 (enExample)
DK (2) DK2173890T3 (enExample)
EA (1) EA021222B8 (enExample)
ES (2) ES2362386T3 (enExample)
HR (1) HRP20110368T1 (enExample)
NZ (1) NZ580670A (enExample)
PL (2) PL2173890T3 (enExample)
PT (1) PT2173890E (enExample)
SI (2) SI2173890T1 (enExample)
WO (1) WO2008155134A1 (enExample)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
PL3050576T3 (pl) 2008-04-29 2021-10-25 Ascendis Pharma Endocrinology Division A/S Pegylowane związki rekombinowanego ludzkiego hormonu wzrostu
AU2009246142A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
CA2726894A1 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
PL2393828T3 (pl) * 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US20110046060A1 (en) * 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
EP2440228B8 (en) 2009-06-08 2023-02-22 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
ES2643641T3 (es) * 2009-06-08 2017-11-23 Amunix Operating Inc. Polipéptidos de hormona del crecimiento y métodos de producción y uso de los mismos
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
BR112012014721B1 (pt) 2009-12-15 2022-06-28 Ascendis Pharma Endocrinology Division A/S Composições de hormônio do crescimento, seus métodos de fabricação, recipiente e kit
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
EP2531206B1 (en) 2010-02-04 2017-05-31 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP3372617B1 (en) * 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
ES2811065T3 (es) 2010-05-11 2021-03-10 Hutchinson Fred Cancer Res Variantes de clorotoxina, conjugados y métodos para su utilización
SI2571510T1 (sl) 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe
CN103124788B (zh) 2010-05-21 2016-01-13 梅里麦克制药股份有限公司 双特异性融合蛋白
CN103038253A (zh) 2010-06-18 2013-04-10 西伯尔科学有限公司 作为用来稳定生物屏障的活性剂的肽
PL2598526T4 (pl) 2010-07-29 2019-05-31 Eleven Biotherapeutics Inc Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1
CN103459415B (zh) 2010-11-26 2021-04-09 分子组合公司 设计的与血清白蛋白结合的重复蛋白
IL210093A0 (en) * 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
KR102110736B1 (ko) 2011-07-08 2020-05-14 바이오버라티브 테라퓨틱스 인크. Viii 인자 키메라 및 하이브리드 폴리펩타이드, 그리고 이들의 사용 방법
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US20140341843A1 (en) 2011-07-29 2014-11-20 Eleven Biotherapeutics, Inc. Purified proteins
AU2012296951B2 (en) * 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
JP6092867B2 (ja) * 2011-08-12 2017-03-08 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN119192402A (zh) 2012-02-15 2024-12-27 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
EP3646880A1 (en) 2012-05-07 2020-05-06 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors
BR112014032316A2 (pt) 2012-06-28 2017-06-27 Molecular Partners Ag proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
PL2882450T3 (pl) 2012-07-11 2020-06-29 Bioverativ Therapeutics Inc. Kompleks czynnika viii z xten i białkiem czynnika von willebranda oraz jego zastosowania
WO2014026054A2 (en) 2012-08-10 2014-02-13 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
US20140092376A1 (en) * 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
WO2014081849A1 (en) 2012-11-20 2014-05-30 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
RU2015126650A (ru) 2012-12-10 2017-01-12 Фред Хатчинсон Кэнсер Рисёрч Сентер Партнеры липокалина по слиянию
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
PL2956477T5 (pl) 2013-02-15 2024-05-27 Bioverativ Therapeutics Inc. Zoptymalizowany gen czynnika viii
CN107693781B (zh) 2013-03-13 2021-11-09 巴扎德制药公司 用于眼部递送的嵌合细胞因子制剂
EP2968581A1 (en) 2013-03-14 2016-01-20 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
EA201890671A1 (ru) 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
AU2014302100B2 (en) 2013-06-28 2020-02-13 Bioverativ Therapeutics Inc. Thrombin cleavable linker with XTEN and its uses thereof
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
DK3041513T3 (da) 2013-09-08 2020-10-26 Kodiak Sciences Inc Zwitterioniske faktor viii-polymerkonjugater
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
HUE047910T2 (hu) 2013-11-05 2020-05-28 Allergan Inc Eljárás a szem állapotainak kezelésére anti-VEGF darpinnal
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
WO2015067791A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
DE102013113156A1 (de) 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
WO2015095553A1 (en) 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
FI4176894T3 (fi) 2014-01-10 2024-05-29 Bioverativ Therapeutics Inc Kimeerisiä tekijä viii -proteiineja ja niiden käyttötarkoituksia
ES2704237T3 (es) 2014-03-05 2019-03-15 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con un aumento de la duración del efecto
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
EP2937096B1 (en) 2014-04-23 2019-08-21 Julius-Maximilians-Universität Würzburg Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
KR20170062490A (ko) 2014-09-26 2017-06-07 바이엘 파마 악티엔게젤샤프트 안정화된 아드레노메둘린 유도체 및 그의 용도
ES2665218T3 (es) 2014-09-30 2018-04-24 Thena Biotech S.r.l. Una proteína de fusión, una nanopartícula compuesta por una pluralidad de monómeros de dicha proteína de fusión y usos de la misma
KR102122463B1 (ko) 2014-10-14 2020-06-15 할로자임, 아이엔씨 아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
SG11201702824UA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
IL251906B2 (en) 2014-11-18 2024-04-01 Ascendis Pharma Endocrinology Div A/S Novel polymeric hgh prodrugs
US12016903B2 (en) 2014-11-21 2024-06-25 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone treatment
WO2016081884A2 (en) 2014-11-21 2016-05-26 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
EP3229845B1 (en) 2014-12-10 2020-05-27 University of Southern California Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
CN107427556B (zh) 2015-02-09 2022-02-25 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
US10478394B2 (en) 2015-03-11 2019-11-19 Wayne State University Compositions and methods to promote wound healing
AU2016240220B2 (en) 2015-04-02 2019-11-21 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
WO2017083491A2 (en) * 2015-11-10 2017-05-18 Proteothera, Inc. Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography
CN109153996B (zh) 2015-12-22 2022-03-25 Xl-蛋白有限责任公司 具有低重复核苷酸序列的编码富含脯氨酸和丙氨酸残基的重复氨基酸序列的核酸
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017118704A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
SMT202200466T1 (it) 2016-01-08 2023-01-13 Ascendis Pharma Growth Disorders As Profarmaci di cnp con legame a supporto in corrispondenza del raggruppamento ciclico
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
ES2929347T3 (es) 2016-01-20 2022-11-28 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con aumento de la duración del efecto
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
SMT202400423T1 (it) 2016-03-01 2024-11-15 Ascendis Pharma Bone Diseases As Profarmaci di pth
AU2017227978B2 (en) 2016-03-02 2022-03-10 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
AR107890A1 (es) 2016-03-10 2018-06-28 Medimmune Ltd Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
AU2017260274A1 (en) * 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
KR102646323B1 (ko) 2016-05-06 2024-03-13 이뮤노포지 주식회사 제어된 지속 방출을 위한 elp 융합 단백질
CA3030376A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
RS64440B1 (sr) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
IL321464A (en) 2016-09-29 2025-08-01 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
PT3518982T (pt) 2016-09-29 2025-01-29 Ascendis Pharma Bone Diseases As Descoberta da dose incremental em compostos de pth de libertação controlada
NZ792622A (en) 2016-09-29 2025-08-29 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018112362A1 (en) 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
CR20190389A (es) 2017-01-31 2019-11-26 Bioverativ Therapeutics Inc Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
IL268781B2 (en) 2017-03-16 2025-09-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
WO2018170021A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
EP3610010A4 (en) 2017-04-14 2021-02-24 Kodiak Sciences Inc. COMPLEMENT FACTOR-D-ANTAGONIST-ANTIBODIES AND CONJUGATES THEREOF
JP7209637B2 (ja) * 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
FI3642340T3 (fi) 2017-06-21 2024-06-18 Jazz Pharmaceuticals Ireland Ltd Muunneltu l-asparaginaasi
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
CN110891612A (zh) 2017-06-21 2020-03-17 Xl-蛋白有限责任公司 蛋白质药物与p/a肽的缀合物
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
WO2019032898A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. NUCLEIC ACID MOLECULES AND USES THEREOF
EA202090974A1 (ru) 2017-10-18 2020-08-05 Элпайн Иммьюн Сайенсиз, Инк. Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы
EA202090897A1 (ru) 2017-11-06 2020-08-28 Тена Байотек С.Р.Л. Новые слитые белки на основе ферритина человека и расщепляемых протеазой пептидов и их применение в качестве носителей химиотерапевтических средств
EP3483619A1 (en) * 2017-11-13 2019-05-15 Technische Universität München Automated noninvasive determining the sex of an embryo of and the fertility of a bird's egg
WO2019126576A1 (en) 2017-12-21 2019-06-27 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
JP2021512126A (ja) 2018-02-01 2021-05-13 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子を発現するレンチウイルスベクターの使用
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
CN120590539A (zh) 2018-03-28 2025-09-05 百时美施贵宝公司 白介素-2/白介素-2受体α融合蛋白以及使用方法
MA52662A (fr) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Div A/S Conjugués d'il-2
CA3093083A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
DK3793587T3 (da) 2018-05-18 2025-07-21 Ascendis Pharma Bone Diseases As Startdosis af pth-konjugater
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN112601517A (zh) 2018-07-03 2021-04-02 百时美施贵宝公司 Fgf-21配制品
SG11202101157VA (en) 2018-08-09 2021-03-30 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2020053206A1 (en) 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
CN111040021B (zh) * 2018-10-12 2023-06-02 浙江道尔生物科技有限公司 一种改善生物活性蛋白性质的载体蛋白
JP2022013959A (ja) * 2018-11-02 2022-01-19 味の素株式会社 融合タンパク質
CN116102621A (zh) 2018-11-07 2023-05-12 浙江道尔生物科技有限公司 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
US20220025344A1 (en) 2018-11-26 2022-01-27 Novartis Ag Lpl-gpihbp1 fusion polypeptides
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
SG11202105880TA (en) 2018-12-06 2021-07-29 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor ix
US12377133B2 (en) 2019-02-11 2025-08-05 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of CNP conjugates
EP3923905A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
CN113573698A (zh) 2019-03-04 2021-10-29 阿森迪斯药物内分泌股份有限公司 与每日生长激素相比具有优异功效的长效生长激素剂型
BR112021020668A2 (pt) 2019-04-17 2022-01-11 Codiak Biosciences Inc Composições de exossomos e aav
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
KR20220016944A (ko) 2019-06-04 2022-02-10 몰리큘라 파트너스 아게 개선된 안정성을 갖는 설계된 안키린 반복 도메인
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
EP3986471A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
CA3143436A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of .pi.-electron-pair-donating heteroaromatic nitrogen-comprising compounds
US20220305129A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
AU2020338947A1 (en) 2019-08-27 2022-03-31 Tonix Pharma Limited Modified TFF2 polypeptides
CA3153803A1 (en) 2019-09-27 2021-04-01 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)
WO2021062374A1 (en) 2019-09-27 2021-04-01 Duke University Tabletization of peptide self-assemblies and methods of making and using the same
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
KR20220123421A (ko) 2020-01-03 2022-09-06 아센디스 파마 에이에스 분자내 재배열 처리된 컨쥬게이트
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
IL294357A (en) 2020-01-13 2022-08-01 Ascendis Pharma Bone Diseases As Hypoparathyroidism treatment
PE20230494A1 (es) 2020-05-08 2023-03-23 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas
JP2023527919A (ja) 2020-06-03 2023-06-30 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｉｌ－２配列及びその使用
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
AU2021319203A1 (en) 2020-07-30 2023-03-02 Silver Creek Pharmaceuticals, Inc. Chimeric proteins and methods of use for treatment of central nervous system disorders
AU2021319863A1 (en) 2020-08-05 2023-02-16 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
TW202219060A (zh) 2020-08-28 2022-05-16 丹麥商阿森迪斯腫瘤製藥有限公司 醣基化il-2蛋白及其用途
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
IL301411A (en) 2020-09-28 2023-05-01 Ascendis Pharma Bone Diseases As Improvement of physical and mental well-being of patients with hypoparathyroidism
CN115925994B (zh) 2020-09-30 2023-09-22 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
US20240018265A1 (en) 2020-12-11 2024-01-18 Friedrich Miescher Institute For Biomedical Research Hdac6 binding proteins and their anti-viral use
JP2024501316A (ja) 2020-12-22 2024-01-11 イクスエル－プロテイン・ゲーエムベーハー 構造的に無秩序な配列に特異的な抗体
MX2023011059A (es) 2021-04-01 2023-09-29 Ascendis Pharma As Uso de hormona del crecimiento de accion prolongada para tratamiento de enfermedades inducidas por inflamacion.
EP4323399A4 (en) 2021-04-14 2025-04-09 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4337668A4 (en) * 2021-05-14 2025-08-13 Antlia Bioscience Inc MODIFIED B-TYPE NATRIURETIC PEPTIDE
TW202313974A (zh) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
AU2022334711A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Baculovirus expression system
WO2023046732A1 (en) 2021-09-22 2023-03-30 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
JP2025512832A (ja) 2022-03-30 2025-04-22 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法
JP2025522281A (ja) 2022-05-23 2025-07-15 アセンディス ファーマ グロース ディスオーダーズ エー／エス Ｃｎｐ化合物の液体医薬製剤
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
AU2023374533A1 (en) 2022-11-02 2025-04-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
WO2025030053A1 (en) 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
WO2025046121A1 (en) 2023-09-01 2025-03-06 Novoarc Gmbh Lipid nanoparticle with nucleic acid cargo and ionizable lipid
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
WO2025088193A1 (en) 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for efficient recombinant production of polypeptides
WO2025088192A1 (en) 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for the coupling of di(alkyl)amines to polypeptides
WO2025233381A1 (en) 2024-05-07 2025-11-13 Technische Universität München, in Vertretung des Freistaates Bayern Enzymes that eliminate pyrimidine and/or purine nucleosides for treating cancer
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
JP2004504016A (ja) 2000-06-30 2004-02-12 マキシゲン・エイピーエス ペプチド拡張されたグリコシル化ポリペプチド
JP5735194B2 (ja) 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド 改善された生体内半減期を有する生物学的に活性なタンパク質
JP4897792B2 (ja) * 2005-04-20 2012-03-14 ビロメッド カンパニー， リミテッド 融合タンパク質の分離のための組成物および方法
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007103515A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
PL2393828T3 (pl) 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Int J Biochem Cell Biol. 37(7):1386-95. (2005. 7)*
Proc Natl Acad Sci U S A. 97(10):5657-62. (2000. 5. 9)*

Also Published As

Publication number Publication date
EA021222B1 (ru) 2015-05-29
EP2173890A1 (en) 2010-04-14
DK2369005T3 (da) 2013-06-24
EA021222B8 (ru) 2015-11-30
HRP20110368T1 (hr) 2011-06-30
DK2173890T3 (da) 2011-06-27
PL2369005T3 (pl) 2013-10-31
EA201000040A1 (ru) 2010-06-30
PL2173890T3 (pl) 2011-07-29
DE602008005596D1 (de) 2011-04-28
JP2010531139A (ja) 2010-09-24
EP2369005B1 (en) 2013-04-03
US8563521B2 (en) 2013-10-22
SI2369005T1 (sl) 2013-09-30
CY1111491T1 (el) 2015-08-05
CA2691386C (en) 2014-12-23
EP2369005A1 (en) 2011-09-28
EP2173890B1 (en) 2011-03-16
US20140050693A1 (en) 2014-02-20
HK1156980A1 (en) 2012-06-22
ATE502114T1 (de) 2011-04-15
CA2691386A1 (en) 2008-12-24
AU2008266448B2 (en) 2013-06-13
SI2173890T1 (sl) 2011-06-30
KR20150092355A (ko) 2015-08-12
NZ580670A (en) 2011-09-30
CN101970678B (zh) 2014-08-20
WO2008155134A1 (en) 2008-12-24
US20100292130A1 (en) 2010-11-18
ES2422007T3 (es) 2013-09-06
AU2008266448A1 (en) 2008-12-24
PT2173890E (pt) 2011-05-06
ES2362386T3 (es) 2011-07-04
JP5351889B2 (ja) 2013-11-27
CN101970678A (zh) 2011-02-09
KR101701080B1 (ko) 2017-01-31
US9260494B2 (en) 2016-02-16
KR20100044732A (ko) 2010-04-30

Similar Documents

Publication Publication Date Title
KR101631323B1 (ko) 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질
JP5828889B2 (ja) プロリン／アラニンランダムコイルポリペプチドの生合成およびその使用
IL303152A (en) Compositions and methods for selective depletion of target molecules
EP0550506B1 (en) Novel chemotactic factor
AU2004293371A1 (en) Methods for obtaining molecules with reduced immunogenicity
CN105085658B (zh) 一种白细胞介素29突变体及聚乙二醇衍生物
AU2013203326B2 (en) Biological active proteins having increased in vivo and/or in vitro stability
HK1156980B (en) Biological active proteins having increased in vivo and/or vitro stability
US6797806B2 (en) Fragments of CR1 and their use
JP6525171B2 (ja) 環状化サイトカイン及びその製法
AU652575B2 (en) Novel chemotactic factor
AU2024280480A1 (en) Il10 inverted monomers
HK1219902B (zh) 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091203

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130121

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130521

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141015

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150528

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141015

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20150626

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150528

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2015101003650

Request date: 20150626

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150727

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20150727

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20150626

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20150114

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150907

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20160325

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20150810

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160610

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160610

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190510

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190510

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20200514

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220512

Start annual number: 7

End annual number: 7